Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Chief Commercial Officer | March 01, 2022 | March 04, 2022 |
| ImageneBio, Inc.IMA · Entity 7139 | Director · Chief Executive Officer | August 14, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 171,415 |
Reported balance
After 2022-03-01 transaction · row 1
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 45,533 · Balance 171,415 F1: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.21 · Expires 2032-02-28 | Direct | 85,592 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 85,592 · Balance 85,592 F2: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
F2: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service.
ImageneBio, Inc.
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 493,705 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 254,800 · Balance 493,705 F1: Represents the number of shares of the Issuer's Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on April 14, 2027, and the remaing RSUs will vest in a series of 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2036-08-13 | Direct | 137,200 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Grant · Acquired 137,200 · Balance 137,200 F2: The options vest over four years, with 25% of the shares vesting on April 14, 2027, and the remaining shares vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2036-08-13 | Direct | 250,000 |
Reported balance
After 2026-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-14 · Grant · Acquired 250,000 · Balance 250,000 F3: The options vest over four years in a series of 48 successive equal monthly installments commencing on May 14, 2026, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on April 14, 2027, and the remaing RSUs will vest in a series of 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
F2: The options vest over four years, with 25% of the shares vesting on April 14, 2027, and the remaining shares vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
F3: The options vest over four years in a series of 48 successive equal monthly installments commencing on May 14, 2026, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Poseida Therapeutics, Inc.
Report date January 08, 2025 · Filed January 08, 2025
Section 16 reporting ended · disclosed 2025-01-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-01-08 transaction · row 1
1 source rowRow 1 · 2025-01-08 · Other · Disposed 615,836 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F3: Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2024, 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2024 and 3,000 shares acquired by the Reporting Person under the ESPP on January 2, 2025. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.62 · Expires 2033-04-10 | Direct | 0 |
Reported balance
After 2025-01-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-08 · Disposition to issuer · Disposed 498,325 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.38 · Expires 2034-01-01 | Direct | 0 |
Reported balance
After 2025-01-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-01-08 · Disposition to issuer · Disposed 345,200 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]
F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
F3: Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2024, 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2024 and 3,000 shares acquired by the Reporting Person under the ESPP on January 2, 2025.
F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5]
F5: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]
F6: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 21:00 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001803794-26-000003 · form4-08172026_050803.xml · derivative · entry 3 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-08-13 F3 · derivative.exercise_date: The options vest over four years in a series of 48 successive equal monthly installments commencing on May 14, 2026, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 21:00 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantEmployee Stock Option (right to buy) · Derivative | 137,200 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001803794-26-000003 · form4-08172026_050803.xml · derivative · entry 2 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,200 Underlying: Common Stock · 137,200 shares Expires 2036-08-13 F2 · derivative.exercise_date: The options vest over four years, with 25% of the shares vesting on April 14, 2027, and the remaining shares vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 21:00 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantCommon Stock | 254,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001803794-26-000003 · form4-08172026_050803.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,705 F1 · shares: Represents the number of shares of the Issuer's Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on April 14, 2027, and the remaing RSUs will vest in a series of 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. Read SEC document |
| July 25, 2026 Filed Jul 28, 2026 20:05 UTC | ImageneBio, Inc. IMA · Entity 7139 | OtherRestricted Stock Units · Derivative | 115,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001803794-26-000002 · form4-07282026_040701.xml · derivative · entry 4 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,129 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: On July 28, 2025, the Reporting Person was granted restricted stock units ("RSUs"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock. F3 · derivative.exercise_date: The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. F3 · derivative.expiration_date: The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. Read SEC document |
| July 25, 2026 Filed Jul 28, 2026 20:05 UTC | ImageneBio, Inc. IMA · Entity 7139 | Exercise / conversionRestricted Stock Units · Derivative | 38,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001803794-26-000002 · form4-07282026_040701.xml · derivative · entry 3 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,129 Underlying: Common Stock · 38,376 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. F3 · derivative.expiration_date: The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. Read SEC document |
| July 25, 2026 Filed Jul 28, 2026 20:05 UTC | ImageneBio, Inc. IMA · Entity 7139 | OtherCommon Stock | 115,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001803794-26-000002 · form4-07282026_040701.xml · nonDerivative · entry 2 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,905 F1 · kind: On July 28, 2025, the Reporting Person was granted restricted stock units ("RSUs"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock. F1 · shares: On July 28, 2025, the Reporting Person was granted restricted stock units ("RSUs"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock. F1 · balance_after: On July 28, 2025, the Reporting Person was granted restricted stock units ("RSUs"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock. Read SEC document |
| July 25, 2026 Filed Jul 28, 2026 20:05 UTC | ImageneBio, Inc. IMA · Entity 7139 | Exercise / conversionCommon Stock | 38,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001803794-26-000002 · form4-07282026_040701.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 22:09 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantEmployee Stock Option (right to buy) · Derivative | 128,100 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001803794-26-000001 · form4-03182026_100308.xml · derivative · entry 2 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,100 Underlying: Common Stock · 128,100 shares Expires 2036-03-16 F2 · derivative.exercise_date: This option vests over four years, with 25% of the shares subject to this option vesting on March 15, 2027, and the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2025 Plan) through each such vesting date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 22:09 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantCommon Stock | 85,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001803794-26-000001 · form4-03182026_100308.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,400 F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on March 15, 2027, and the balance will vest in successive equal quarterly installments on each of the next 12 Standard Quarterly Dates thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan")) through each such vesting date. The "Standard Quarterly Dates" are each of March 15, June 15, September 15 and December 15. Read SEC document |
| July 28, 2025 Filed Jul 31, 2025 01:30 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantRestricted Stock Units · Derivative | 153,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020660 · form4-07312025_010741.xml · derivative · entry 2 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,505 Underlying: Common Stock · 153,505 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (collectively, the "RSUs") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. F3 · derivative.expiration_date: The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. Read SEC document |
| July 28, 2025 Filed Jul 31, 2025 01:30 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 460,515 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001415889-25-020660 · form4-07312025_010741.xml · derivative · entry 1 Yarema Kristin · CIK 0001803794 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,515 Underlying: Common Stock · 460,515 shares Expires 2035-07-27 F1 · derivative.exercise_date: This option vests over four years, with 25% of the shares subject to this option vesting on July 25, 2026, and the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 14:07 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 345,200 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001415889-25-001080 · form4-01082025_070130.xml · derivative · entry 3 Yarema Kristin · CIK 0001803794 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 345,200 shares Expires 2034-01-01 F4 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 14:07 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 498,325 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001415889-25-001080 · form4-01082025_070130.xml · derivative · entry 2 Yarema Kristin · CIK 0001803794 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 498,325 shares Expires 2033-04-10 F4 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 14:07 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | OtherCommon Stock | 615,836 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001080 · form4-01082025_070130.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2 · shares: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F3 · shares: Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2024, 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2024 and 3,000 shares acquired by the Reporting Person under the ESPP on January 2, 2025. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2 · price: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:03 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantStock Option (Right to buy) · Derivative | 345,200 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000950170-24-001835 · ownership.xml · derivative · entry 2 Yarema Kristin · CIK 0001803794 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,200 Underlying: Common Stock · 345,200 shares Expires 2034-01-01 F2 · derivative.exercise_date: 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of January 1, 2024, and the remaining shares will vest in 42 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:03 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001835 · ownership.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 606,836 F1 · kind: Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments beginning from the first anniversary of January 1, 2024. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 16:49 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantEmployee Stock Option (Right to Buy) · Derivative | 498,325 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-23-024103 · doc4.xml · derivative · entry 2 Yarema Kristin · CIK 0001803794 · President, Cell Therapy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,325 Underlying: Common Stock · 498,325 shares Expires 2033-04-10 F2 · derivative.exercise_date: 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 16:49 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantCommon Stock | 356,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024103 · doc4.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · President, Cell Therapy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,836 F1 · kind: Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's 2022 Inducement Plan. The RSUs are scheduled to vest in four equal annual installments. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 85,592 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001140361-22-007766 · form4.xml · derivative · entry 2 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,592 Underlying: Common Stock · 85,592 shares Expires 2032-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 45,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-007766 · form4.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,415 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 20:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | PurchaseCommon Stock | 28,833 | $14.58 | $420,385.14 |
DisclosureSEC source: 0001567619-21-012110 · doc1.xml · nonDerivative · entry 3 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,882 F1 · kind: The reporting person's sale of ATRA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 761 shares, with the reporting person's sale of 761 shares of ATRA common stock at a weighted average price of $14.55 per share on May 18, 2021. The reporting person has agreed to pay to ATRA $53.27, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 20:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | PurchaseCommon Stock | 3,500 | $14.48 | $50,680.00 |
DisclosureSEC source: 0001567619-21-012110 · doc1.xml · nonDerivative · entry 2 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,049 F1 · kind: The reporting person's sale of ATRA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 761 shares, with the reporting person's sale of 761 shares of ATRA common stock at a weighted average price of $14.55 per share on May 18, 2021. The reporting person has agreed to pay to ATRA $53.27, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | PurchaseCommon Stock | 2,021 | $14.50 | $29,304.50 |
DisclosureSEC source: 0001567619-21-012110 · doc1.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,549 F1 · kind: The reporting person's sale of ATRA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 761 shares, with the reporting person's sale of 761 shares of ATRA common stock at a weighted average price of $14.55 per share on May 18, 2021. The reporting person has agreed to pay to ATRA $53.27, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 761 | $14.55 | $11,072.55 |
DisclosureSEC source: 0001209191-21-034422 · doc4.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,528 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 52,862 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-21-017037 · doc4.xml · derivative · entry 2 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,862 Underlying: Common Stock · 52,862 shares Expires 2031-02-28 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 35,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017037 · doc4.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,289 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2021, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. F2 · balance_after: Includes 2,268 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 22:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015360 · doc4.xml · nonDerivative · entry 1 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · kind: These restricted stock units vest as to 25% of the shares on March 1, 2021 and the remaining shares vest in 12 equal quarterly installments on each Company Quarterly Vesting Date (as defined below) following March 1, 2021, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 01:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-20-010848 · doc4.xml · derivative · entry 1 Yarema Kristin · CIK 0001803794 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 18, 2021 and the remaining shares vest in equal monthly installments over the following 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.